D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 12.71 USD -0.63%
Market Cap: 1.3B USD
Have any thoughts about
Day One Biopharmaceuticals Inc?
Write Note

Gross Margin
Day One Biopharmaceuticals Inc

97.8%
Current
15%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.8%
=
Gross Profit
99.7m
/
Revenue
102m

Gross Margin Across Competitors

Country US
Market Cap 1.3B USD
Gross Margin
98%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.2B USD
Gross Margin
67%
Country US
Market Cap 142B USD
Gross Margin
60%
Country US
Market Cap 115B USD
Gross Margin
78%
Country US
Market Cap 101.6B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78.5B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Day One Biopharmaceuticals Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs. Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.

DAWN Intrinsic Value
13.54 USD
Undervaluation 6%
Intrinsic Value
Price
D

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
97.8%
=
Gross Profit
99.7m
/
Revenue
102m
What is the Gross Margin of Day One Biopharmaceuticals Inc?

Based on Day One Biopharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 97.8%.